AVDL News and Press, Avadel Pharmaceuticals plc From 05/08/24

2024-05-08 12:52:04 ET Avadel Pharmaceuticals plc (AVDL) Q1 2024 Earnings Conference Call May 08, 2024 08:30 am ET Company Participants Austin Murtagh - Director at Stern Investor Relations Gregory Divis - CEO Richard Kim - Chief Commercial Officer Thomas McH...

2024-05-08 07:49:55 ET More on Avadel Pharmaceuticals plc Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang Avadel surges after royalty rate awarded to Jazz in paten...

Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...

-- Generated $27.2 million in net revenue from sales of LUMRYZ™ -- -- Through March 31, greater than 2,800 patients enrolled in Avadel’s RYZUP patient support services and more than 1,700 patients initiated therapy -- -- Pursuing expansion opportunities for LUMRYZ ...

2024-05-07 11:18:44 ET More on Avadel Pharmaceuticals plc Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang Avadel surges after royalty rate awarded to Jazz in paten...

Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...

DUBLIN, Ireland, May 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 8, 2024, to provide...

2024-04-18 13:26:38 ET Summary Jazz Pharmaceuticals plc has a neuroscience franchise that is led by Xywav, which has replaced Xyrem as the top treatment for narcolepsy. The company's narcolepsy franchise is facing competition from Avadel Pharmaceuticals' Lumryz, but Jazz is defend...

2024-04-09 19:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-02 03:40:17 ET Summary Avadel Pharmaceuticals reports strong Q4 2023 earnings for Lumryz, its once-nightly formulation of sodium oxybate for narcolepsy. Lumryz fills a significant gap in narcolepsy treatment by offering a more patient-friendly dosing schedule and improving...